Please use this identifier to cite or link to this item:
Title: Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development.
Austin Authors: Bialer, Meir;Johannessen, Svein I;Koepp, Matthias J;Levy, René H;Perucca, Emilio;Perucca, Piero ;Tomson, Torbjörn;White, H Steve
Affiliation: Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London, UK..
Institute for Drug Research, Faculty of Medicine, School of Pharmacy, and David R. Bloom Center for Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel..
Medicine (University of Melbourne)
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia..
Comprehensive Epilepsy Program
Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia..
Department of Neurology, Alfred Health, Melbourne, Victoria, Australia..
National Center for Epilepsy, Sandvika, Norway..
Department of Pharmaceutics and Neurological Surgery, University of Washington, Seattle, Washington, USA..
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden..
Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington, USA..
Department of Pharmacology, Oslo University Hospital, Oslo, Norway..
Issue Date: 11-Aug-2022 2022
Publication information: Epilepsia 2022; 63(11)
Abstract: The Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI) was held in Madrid, Spain on May 22-25, 2022 and was attended by 157 delegates from 26 countries representing basic and clinical science, regulatory agencies, and pharmaceutical industries. One day of the conference was dedicated to sessions presenting and discussing investigational compounds under development for the treatment of seizures and epilepsy. The current progress report summarizes recent findings and current knowledge for seven of these compounds in more advanced clinical development for which either novel preclinical or patient data are available. These compounds include bumetanide and its derivatives, darigabat, ganaxolone, lorcaserin, soticlestat, STK-001, and XEN1101. Of these, ganaxolone was approved by the US Food and Drug Administration in March 2022 for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients 2 years of age and older.
DOI: 10.1111/epi.17376
ORCID: 0000-0003-2046-4171
Journal: Epilepsia
PubMed URL: 35950617
PubMed URL:
Type: Journal Article
Subjects: antiepileptic drugs
antiseizure medications
drug development
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 2, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.